Kurin Unveils Ventless Kurin Jet

Kurin Inc. has initiated the limited commercial release of Kurin Jet, a technological advancement over Kurin Lock. The new ventless device is not at issue in the lawsuit with Magnolia Medical.
 
“We are excited to announce the introduction of Kurin Jet, a fundamentally different product that provides a new level of performance in addressing the blood culture contamination market” Kurin CEO Bob Rogers said. “Although our current Kurin Lock is the market leader because of its small size and passive, user-friendly design, we have leapfrogged that technology and created a much faster device with a greater level of control for clinicians. Kurin Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”
 
Kurin’s approach to the contaminated blood culture problem is based on simple, intuitive designs that require no additional user steps. Like the Kurin Lock, Kurin Jet passively sidelines potential contaminants during blood culture collection. Kurin Lock and Kurin Jet both provide a better and more sustainable approach than active, conventional mechanical diversion, according to the company. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

“Kurin Jet helps hospitals address the significant challenge of blood culture contamination with its unique design, speed, and ease of use,” Rogers stated. “Based on its performance and feedback from those who have used Jet, we will limit the initial release, as demand will exceed initial production volumes. Full release will occur later this year.”
 
Kurin Inc., a certified Minority Business Enterprise (MBE), designs, develops, manufactures, markets, and sells products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received U.S. Food and Drug Administration 510(k) market clearance.